A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Merck’s stock fell Thursday morning, despite the company beating profit and sales estimates for the third quarter.
Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...
Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.
Merck & Co. Inc.’s stock swung between gains and losses premarket Thursday, after the drug company beat profit and sales estimates for the third quarter, but lowered guidance due to deals with ...
Outlook Reflects a Net Negative Impact of $0.24 per Share Related to Business Development Transactions With Curon Biopharmaceutical and Daiichi Sankyo Merck (NYSE: MRK), known as MSD outside the ...
Merck & Co. Inc.'s stock fell 3% Thursday ... charges stemming from deals with partners Curon Biopharmaceutical and Daiichi Sankyo. The Rahway, N.J.-based company (MRK) posted net income of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback